Ausgabe 12/ 2009, S. 30
Zurück zum Inhaltsverzeichnis
Fortbildung | CME Neurologie

Antidepressiva, Antidementiva und Neuroleptika:

Wann braucht der Parkinsonpatient welches Medikament?

Rejko Krüger und Daniel Weiss, Tübingen

Aufgrund der Fortschritte in der pharmakologischen Therapie der Parkinsonkrankheit seit der Einführung des dopaminergen Therapieprinzips in den 1970er-Jahren steht dem behandelnden Arzt heute ein Vielzahl von Substanzen zur Verfügung, die eine hocheffektive individualisierte symptomatische Therapie der motorischen Symptomatik erlauben.

Korrespondenzadresse
Prof. Dr. med. Rejko Krüger
Neurologie mit Schwerpunkt Neurodegenerative Erkrankungen und Hertie-Institut für Klinische Hirnforschung,
Universität Tübingen,
Hoppe-Seyler-Str. 3,
D-72076 Tübingen,
Tel.: 07071/29-82340,
Fax: 07071/29-5260
E-Mail: rejko.krueger@uni-tuebingen.de

Literatur

  1. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006;248:151-157.
  2. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat Disord 2007;13 Suppl:S2-7.
  3. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-189; quiz 313.
  4. Barone P, Goetz CG, Houben LJ, et al. Prodest - depressive symptoms in Parkinson's disease: demographic data. Eur J Neurol 2007;14:61.
  5. Lemke MR. Depressive symptoms in Parkinson's disease. Eur J Neurol 2008;15 Suppl 1:21-25.
  6. Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. Mov Disord 2000;15:216-223.
  7. Taylor AE, Saint-Cyr JA. Depression in Parkinson's disease: reconciling physiological and psychological perspectives. J Neuropsychiatry Clin Neurosci 1990;2:92-98.
  8. Yamamoto M. Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background. J Neurol 2001;248 Suppl 3:III5-11.
  9. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005;20:1161-1169.
  10. Menza M, Dobkin RD, Marin H, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov Disord 2009;24:1325-1332.
  11. Serrano-Duenas M. Dosis bajas de amitriptilina frente a dosis bajas de fluoxetine en el tratamiento de la depression de enfermos con Parkinson. Rev Neurol 2002;35:1010–1014.
  12. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892.
  13. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neurol Scand 1980;62:210-219.
  14. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, plazebo-controlled study. Mov Disord 2008;23:850-857.
  15. Serrano-Dueñas M. [A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease]. Rev Neurol 2002;35:1010-1014.
  16. Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM. Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. J Geriatr Psychiatry Neurol 2007;20:161-165.
  17. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 1997;49:1168-1170.
  18. Wermuth L SP, Timm S, et al. Depression in idiopathic Parkinson’s disease treated with citalopram: a plazebo-controlled trial. Nord J Psychiatry 1998;52:163-169.
  19. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000;15:986-989.
  20. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000;55:1216-1218.
  21. Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord 2006;21:1119-1122.
  22. Pintor L, Bailles E, Valldeoriola F, Tolosa E, Marti MJ, de Pablo J. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. Gen Hosp Psychiatry 2006;28:59-64.
  23. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300-304.
  24. Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007;30:201-205.
  25. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 1984;34:1092-1094.
  26. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and plazebo in patients with major depression. Depress Anxiety 2000;11:58-65.
  27. Lattanzi L, Dell'Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002;4:307-314.
  28. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006;253:601-607.
  29. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10:399-406.
  30. Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005;20:602-610.
  31. Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of plazebo-controlled studies. Clin Ther 2009;31:89-98.
  32. Okun MS, Fernandez HH. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? Neurology 2009;72:868-869.
  33. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 2008;255:255-264.
  34. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996;53:538-542.
  35. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology 2002;59:1708-1713.
  36. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
  37. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
  38. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006:CD004747.
  39. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.
  40. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, plazebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-939.
  41. Goetz CG. Hallucinations in Parkinson's disease: the clinical syndrome. Adv Neurol 1999;80:419-423.
  42. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996;53:1265-1268.
  43. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999;340:757-763.
  44. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 1999;353:2041-2042.
  45. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59 Suppl 3:3-7.
  46. Rupprecht R, Soyka M, Grohmann R, Ruther E, Moller HJ. [Considerations in the combination of clozapine and benzodiazepines]. Nervenarzt 2004;75:857-860.
  47. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-1035.
  48. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Mov Disord 2002;17:221-222.
  49. Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002;17:676-681.
  50. Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002;23 Suppl 2:S89-90.
  51. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002;25:107-110.
  52. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002;18:258-264.
  53. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-1907.